Toward an Ethically Sensitive Implementation of Noninvasive Prenatal Screening in the Global Context

Hastings Center Report

Volumn 47, Issue 2, 2017, Pages 41-49

  Mozersky, Jessica ^a   Ravitsky, Vardit ^a   Rapp, Rayna ^a   Michie, Marsha ^a   Chandrasekharan, Subhashini ^a   Allyse, Megan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA SCREENING; EUROPE; FOLLOW UP; HUMAN; MATERNAL CARE; MIDDLE INCOME COUNTRY; NORTH AMERICA; PRENATAL SCREENING; DECISION MAKING; ETHICS; GENETIC SCREENING; GLOBAL HEALTH; PERSONAL AUTONOMY; PRENATAL DIAGNOSIS; SEX SELECTION; SOCIOECONOMICS; WOMEN'S HEALTH;

DECISION MAKING; GENETIC TESTING; GLOBAL HEALTH; HUMANS; PERSONAL AUTONOMY; PRENATAL DIAGNOSIS; SEX PRESELECTION; SOCIOECONOMIC FACTORS; WOMEN'S HEALTH;

EID: 85015664393     PISSN: 00930334     EISSN: 1552146X     Source Type: Journal    
DOI: 10.1002/hast.690     Document Type: Article

References (59)

1. P. Benn, H. Cuckle, and E. Pergament, “Non-invasive Prenatal Diagnosis for Down Syndrome: The Paradigm Will Shift, but Slowly,” Ultrasound in Obstetrics & Gynecology 39, no. 2 (2012): 127–30.
2. D. W. Bianchi et al., “DNA Sequencing versus Standard Prenatal Aneuploidy Screening,” New England Journal of Medicine 370, no. 9 (2014): 799–808.
3. D. W. Bianchi and L. Wilkins-Haug, “Integration of Noninvasive DNA Testing for Aneuploidy into Prenatal Care: What Has Happened Since the Rubber Met the Road?,” Clinical Chemistry 60, no. 1 (2014): 78–87;
4. “Clinical NGS Market in China Poised to Take Off as China FDA Looks to Establish Guidelines,” GenomeWeb, accessed December 29, 2015, https://www.genomeweb.com/sequencing-technology/clinical-ngs-market-china-poised-take-china-fda-looks-establish-guidelines.
5. M. A. Minear et al., “Global Perspectives on Clinical Adoption of NIPT,” Prenatal Diagnosis 35, no. 10 (2015): 959–67.
6. W. Dondorp et al., “Non-invasive Prenatal Testing for Aneuploidy and Beyond: Challenges of Responsible Innovation in Prenatal Screening,” European Journal of Human Genetics 23 (2015): 1438–50.
7. A. Agarwal et al., “Commercial Landscape of Noninvasive Prenatal Testing in the United States,” Prenatal Diagnosis 33, no. 6 (2013): 521–31.
8. Dondorp et al., “Non-invasive Prenatal Testing for Aneuploidy and Beyond.”
9. R. M. Farrell et al., “It's More Than a Blood Test: Patients’ Perspectives on Noninvasive Prenatal Testing,” Journal of Clinical Medicine 3, no. 2 (2014): 614–31;
10. S. Chetty, M. J. Garabedian, and M. E. Norton, “Uptake of Noninvasive Prenatal Testing (NIPT) in Women Following Positive Aneuploidy Screening,” Prenatal Diagnosis 33, no. 6 (2013): 542–46.
11. Minear et al., “Global Perspectives on Clinical Adoption of NIPT”;
12. Dondorp et al., “Non-invasive Prenatal Testing for Aneuploidy and Beyond.”
13. S. Chandrasekharan et al., “Noninvasive Prenatal Testing Goes Global,” Science Translational Medicine 6, no. 231 (2014): 231fs15;
14. M. Allyse et al., “Non-invasive Prenatal Testing: A Review of International Implementation and Challenges,” International Journal of Women's Health 7 (2015): 113–26;
15. Minear et al., “Global Perspectives on Clinical Adoption of NIPT”;
16. H. Haidar et al., “Noninvasive Prenatal Testing: Implications for Muslim Communities,” AJOB Empirical Bioethics 6, no. 1 (2015): 94–105.
17. Titled Non-Invasive Prenatal Testing in the Non-Western Context, the workshop was held December 14-17, 2015.
18. Clinical NGS“ Market in China Poised to Take Off as China FDA Looks to Establish Guidelines,” GenomeWeb, accessed December 29, 2015, https://www.genomeweb.com/sequencing-technology/clinical-ngs-market-china-poised-take-china-fda-looks-establish-guidelines.
19. C. Mackenzie and N. Stoljar, Relational Autonomy: Feminist Perspectives on Autonomy, Agency, and the Social Self (Oxford: Oxford University Press, 2000).
20. B. Jennings, “Reconceptualizing Autonomy: A Relational Turn in Bioethics,” Hastings Center Report 46, no. 3 (2016): 11-16, at 11.
21. As part of our efforts to avoid implicit assumptions, we agreed to avoid terminology such as “developed” or “developing,” “First” and “Third World,” and “non-Western” in favor of “low- and middle-income countries” (or “LMIC”).
22. Mackenzie and Stoljar, Relational Autonomy.
23. F. Moazam, “Feminist Discourse on Sex Screening and Selective Abortion of Female Foetuses,” Bioethics 18, no. 3 (2004): 205–20.
24. Mackenzie and Stoljar, Relational Autonomy.
25. Ibid., 13.
26. Jennings, “Reconceptualizing Autonomy”;
27. A. van den Heuvel et al., “Is Informed Choice in Prenatal Testing Universally Valued? A Population-Based Survey in Europe and Asia,” BJOG: An International Journal of Obstetrics & Gynaecology 116, no. 7 (2009): 880–85.
28. L. Otaño and L. Igarzábal, “Noninvasive Prenatal Testing for Fetal Aneuploidy in Argentina,” AJOB Empirical Bioethics 6, no. 1 (2015): 111–14.
29. F. Luna, “Elucidating the Concept of Vulnerability: Layers Not Labels,” International Journal of Feminist Approaches to Bioethics 2, no. 1 (2009): 121–39.
30. “An Overview of Abortion Laws,” Guttmacher Institute, March 9, 2016, https://www.guttmacher.org/state-policy/explore/overview-abortion-laws.
31. A. P. Dervan et al., “Payer Decision Making for Next-Generation Sequencing-Based Genetic Tests: Insights from Cell-Free DNA Prenatal Screening,” Genetics in Medicine (2016), doi:10.1038/gim.2016.145.
32. Luna, “Elucidating the Concept of Vulnerability.”
33. K. Madan and M. H. Breuning, “Impact of Prenatal Technologies on the Sex Ratio in India: An Overview,” Genetics in Medicine 16, no. 6 (2014): 425–32.
34. Sex selection can also be used to avoid certain sex-linked disorders, but it is not referred to as family balancing in this context. Genetics & IVF Institute, “Family Balancing,” accessed October 18, 2016, http://www.givf.com/familybalancing/.
35. C. Kaposy, “A Disability Critique of the New Prenatal Test for Down Syndrome,” Kennedy Institute of Ethics Journal 23, no. 4 (2013): 299–324.
36. P. Devlieger, F. R. Rusch, and D. Pfeiffer, Rethinking Disability: The Emergence of New Definitions, Concepts and Communities (Antwerp, Belgium: Garant, 2003);
37. B. Ingstad and S. Reynolds Whyte, Disability in Local and Global Worlds (Berkeley, CA: University of California Press, 2007);
38. T. M. Gammeltoft, Haunting Images: A Cultural Account of Selective Reproduction in Vietnam, 1st ed. (Berkeley, CA: University of California Press, 2014).
39. J. H. Nazer, A. R. Aguila, and L. O. Cifuentes, “[Increasing Rates of Down Syndrome among Newborns in Chile from 1972 to 2005],” Revista Médica De Chile 134, no. 12 (2006): 1549–57.
40. T. Ivry, Embodying Culture: Pregnancy in Japan and Israel (New Brunswick, NJ: Rutgers University Press, 2009).
41. S. J. Dyer et al., “Men Leave Me As I Cannot Have Children’: Women's Experiences with Involuntary Childlessness,” Human Reproduction 17, no. 6 (2002): 1663–68.
42. N. E. Cousens et al., “Carrier Screening for Beta-Thalassaemia: A Review of International Practice,” European Journal of Human Genetics: EJHG 18, no. 10 (2010): 1077–83.
43. Chandrasekharan et al., “Noninvasive Prenatal Testing Goes Global.”
44. “Prenatal Diagnostics Market—Global Segments and Forecasts up to 2018: Transparency Market Research,” accessed October 18, 2016, http://www.transparencymarketresearch.com/prenatal-diagnostics-market.html.
45. M. Allyse and S. Chandrasekharan, “Too Much, Too Soon?: Commercial Provision of Noninvasive Prenatal Screening for Subchromosomal Abnormalities and Beyond,” Genetics in Medicine: Official Journal of the American College of Medical Genetics 17, no. 12 (2015): 985–61.
46. J. Mozersky and M. T. Mennuti, “Cell-Free Fetal DNA Testing: Who Is Driving Implementation?,” Genetics in Medicine 15, no. 6 (2013): 433–34;
47. B. Murdoch et al., “Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process,” Journal of Obstetrics and Gynaecology Canada 39, no. 1 (2017): 10–17.
48. Minear et al., “Global Perspectives on Clinical Adoption of NIPT.”
49. K. K. Lo et al., “Limited Clinical Utility of Non-invasive Prenatal Testing for Subchromosomal Abnormalities,” American Journal of Human Genetics 98, no. 1 (2016): 34–44;
50. V. Ravitsky, F. Rousseau, and A.-M. Laberge, “Providing Unrestricted Access to Prenatal Testing Does Not Translate to Enhanced Autonomy,” American Journal of Bioethics 17, no. 1 (2017): 39–41.
51. Allyse et al., “Non-invasive Prenatal Testing.”
52. Luna, “Elucidating the Concept of Vulnerability.”
53. Dondorp et al., “Non-invasive Prenatal Testing for Aneuploidy and Beyond.”
54. Devlieger, Rusch, and Pfeiffer, Rethinking Disability.
55. Cyprus and Iran are exceptions and have successfully reduced the incidence of hemoglobinopathies through education, premarital, and prenatal screening programs.
56. Allyse et al., “Non-invasive Prenatal Testing”;
57. National Society of Genetic Counselors, “Find a Genetic Counselor,” accessed October 18, 2016, http://nsgc.org/p/cm/ld/fid=164.
58. B. Daley, “Oversold Prenatal Tests Spur Some to Choose Abortions,” Boston Globe, December 14, 2014.
59. P. Dar et al., “Clinical Experience and Follow-up with Large Scale Single-Nucleotide Polymorphism–Based Noninvasive Prenatal Aneuploidy Testing,” American Journal of Obstetrics & Gynecology 211, no. 5 (2014): 527.e1–527.e17.